Butorphanol


Thông tin thuốc gốc
Chỉ định và Liều dùng
Nasal
Moderate to severe pain
Adult: As metered-dose spray: Initially, 1 mg (1 spray in 1 nostril), repeated after 60-90 min if needed; sequence may be repeated after 3-4 hr when necessary. Severe pain: 2 mg (1 spray into each nostril), may only be repeated after 3-4 hr.
Elderly: Initially, 1 mg, repeated after 90-120 min if needed. Subsequent doses may be given if necessary at intervals of ≥6 hr.

Parenteral
Moderate to severe pain
Adult: 1-4 mg via IM inj or 0.5-2 mg via IV inj, repeated after 3-4 hr if necessary.
Elderly: Initiate at half the usual dose. Adjust subsequent doses according to response at intervals of ≥6 hr.

Parenteral
Anaesthesia
Adult: As premedication: 2 mg via IM inj 60-90 min prior to surgery. As balanced anaesth: 2 mg via IV inj before induction and/or 0.5-1 mg in increments during anaesth.

Parenteral
Obstetric analgesia
Adult: 1-2 mg via IM or IV inj during early labour, may be repeated after 4 hr, if necessary.
Renal Impairment
Moderate to severe pain
Parenteral:
Initiate at half the usual dose. Adjust subsequent doses according to response at intervals of ≥6 hr.
Nasal:
Initially, 1 mg, repeated after 90-120 min if needed. Subsequent doses may be given if necessary at intervals of ≥6 hr.
Hepatic Impairment
Moderate to severe pain
Parenteral:
Initiate at half the usual dose. Adjust subsequent doses according to response at intervals of ≥6 hr.
Nasal:
Initially, 1 mg, repeated after 90-120 min if needed. Subsequent doses may be given if necessary at intervals of ≥6 hr.
Tương kỵ
Y-site admin: Incompatible w/ amphotericin B cholesteryl sulfate complex, midazolam. Syringe: Incompatible w/ dimenhydrinate, pentobarbital.
Chống chỉ định
Significant resp depression, unmonitored acute or severe brochial asthma.
Thận trọng
Patient w/ head injury, increased intracranial pressure, acute MI, ventricular dysfunction, coronary insufficiency, adrenal insufficiency, biliary tract dysfunction, CNS depression, prostatic hyperplasia, hypercapnia/hypoxia, COPD, thyroid dysfunction; obese patients and those at risk for drug abuse. Renal and hepatic impairment. Elderly. Pregnancy (may cause neonatal opioid withdrawal syndrome in prolonged use during pregnancy) and lactation.
Phản ứng phụ
Asthenia/lethargy, headache, heat sensation, vasodilation, palpitations, anorexia, constipation, dry mouth, nausea and vomiting, stomach pain, anxiety, confusion, dizziness, euphoria, floating feeling, insomnia, nervousness, paraesthesia, somnolence, tremor, bronchitis, cough, dyspnoea, epistaxis, nasal congestion, nasal irritation, pharyngitis, rhinitis, sweating, pruritus, blurred vision, ear pain, tinnitus, unpleasant taste, hypotension, syncope, abnormal dreams, agitation, dysphoria, hallucinations, hostility, rash, impaired urination, oedema, chest pain, HTN, tachycardia, depression, shallow breathing.
Potentially Fatal: Resp depression.
IM/IV/Nasal/Parenteral: C
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness and dizziness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor pain relief, resp and mental status, BP, signs and symptoms of hypogonadism or hypoadrenalism.
Quá liều
Symptoms: Resp depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary oedema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring. Management: Supportive treatment. Immediate IV admin of an opiate antagonist (e.g. naloxone or nalmefene) as specific antidote. Administer oxygen, IV fluids and vasopressors as necessary.
Tương tác
Additive effect w/ other CNS depressants (e.g. general anaesth, phenothiazines or other tranquilizers, sedatives, hypnotics, antihistamines). May increase risk of transient high BP when used w/ sumatriptan nasal spray. Increased conjunctival changes when used w/ pancuronium. Decreased rate of absorption when used w/ oxymetazoline (nasal).
Food Interaction
Additive CNS depressant effect w/ alcohol.
Tác dụng
Description: Butorphanol is a phenanthrene derivative w/ mixed opioid agonist and antagonist effect. It causes inhibition of ascending pain pathways, thus alters the perception of and response to pain. It also produces resp depression and sedation similar to opioids.
Onset: ≤15 min (IM, nasal).
Duration: 3-4 hr (IV, IM); 4-5 hr (nasal).
Pharmacokinetics:
Absorption: Rapidly and well absorbed. Bioavailability: 60-70% (nasal). Time to peak plasma concentration: 0.5-1 hr (IM, IV); 1-2 hr (nasal).
Distribution: Crosses the placenta and enters breast milk. Volume of distribution: 305-901 L. Plasma protein binding: Approx 80%.
Metabolism: Metabolised hepatically to hydroxybutorphanol as major metabolite.
Excretion: Via urine (approx 70-80%, 5% as unchanged); faeces (approx 15%). Elimination half-life: Approx 2-9 hr (IV, nasal).
Đặc tính

Chemical Structure Image
Butorphanol

Source: National Center for Biotechnology Information. PubChem Database. Butorphanol, CID=5361092, https://pubchem.ncbi.nlm.nih.gov/compound/Butorphanol (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Phân loại ATC
N02AF01 - butorphanol ; Belongs to the class of morphinan derivative opioids. Used to relieve pain.
References
Anon. Butorphanol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/09/2016.

Buckingham R (ed). Butorphanol Tartrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/09/2016.

Butorphanol Tartrate Injection, Solution (Hospira Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/09/2016.

Butorphanol Tartrate Solution (Apotex Corp). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/09/2016.

Butorphanol Tartrate Spray, Metered (Roxane Laboratories, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/09/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Butorphanol Tartrate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/09/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Butorphanol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in